AOD-9604 vs MOTS-c: What the Research Shows
AOD-9604 and MOTS-c side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider AOD-9604 if…
No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.
Consider MOTS-c if…
- you are weighing human evidence that, in our search, only measured the body's own MOTS-c (none gave it as a treatment): exercise raised plasma MOTS-c in non-Hispanic White survivors but not Hispanic survivors[10]
What they have in common
- Only animal or lab studies of AOD-9604 were found (e.g. rat): Oral AOD9604 for 19 days cut body weight gain by over 50% (15.8 g vs 35.6 g control) in obese Zucker rats.[5]
Spec comparison
Showing 10 of 12 fields where the two differ. Category, Half-life are the same or both unknown.
| Field | AOD-9604 | MOTS-c |
|---|---|---|
| Class | HGH fragment analog | Mitochondrial-derived peptide |
| Also called | AOD | mots |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Not FDA approved · research chemical | PCAC voted 7–5 for 503A (Jul 2026) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | PCAC voted 7–5 for the 503A list (Jul 2026); not finalized |
| WADA | Prohibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times. | Prohibited by WADA (S4.4.1)MOTS-c is named in S4.4.1 (metabolic modulators: AMPK activators), prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | No published half-life foundPubMed search, 11 Oct 2026 | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Animal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694 | Human RCT evidence, 4 of 4Strongest: Medicine and science in sports and exercise 2025, PMID 40674654 |
| Human studies we summarised | 0 human (0 randomized or controlled) of 4 summarised | 7 human (4 randomized or controlled) of 15 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg | 5 mg, 10 mg, 20 mg, 40 mg |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
AOD-9604 and MOTS-c together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 1 result, 2 Oct 2026).
The two peptides were asked different questions in different animals
In obese mice, chronic AOD9604 reduced body-weight gain, which was associated with increased in vivo fat oxidation and raised plasma glycerol, an index of lipolysis.[20]
In ovariectomised mice, MOTS-c treatment prevented obesity and insulin resistance.[21]
MOTS-c was also reported to enhance physical performance in young (2 months), middle-aged (12 months) and old (22 months) mice.[22]
In a collagenase-induced knee osteoarthritis model in rabbits, intra-articular AOD9604 injections enhanced cartilage regeneration, and AOD9604 combined with hyaluronic acid worked better than either alone.[4]
Where humans enter the picture
The human MOTS-c papers cited here measure the peptide's own blood levels. In one, repeated heat treatment raised circulating MOTS-c (P = 0.033); no one was given MOTS-c.[8]
The only human item cited for AOD-9604 is a drug profile noting that by February 2002 phase IIa trials were underway. No trial results are quoted.[23]
Common questions
AOD-9604 vs MOTS-c: which is better for fat loss?
The cited evidence for both is animal work. In obese mice, AOD9604 and growth hormone both significantly reduced body weight gain; the MOTS-c obesity data cited here are also from mice.[20]
Has MOTS-c been tested in people the way AOD-9604 was?
A drug profile reported AOD-9604 phase IIa trials underway by February 2002. The MOTS-c human papers cited here measured the body's own levels instead.[23]
Which one affects blood sugar?
In mice, MOTS-c ameliorated the development of hyperglycemia and reduced islet-infiltrating immune cells in an autoimmune-diabetes model.[24]
Sources
- 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
- 4Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
- 5Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
- 6PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes.Rapid communications in mass spectrometry : RCM · 2019PMID 30394592Accessed 2 Oct 2026
- 8Repeated Heat Stress Modulates the Levels of the Mitokines MOTS-C and FGF21 in Active Men during Calf Muscle Immobilization.Medicine and science in sports and exercise · 2025PMID 40674654Accessed 2 Oct 2026
- 9Circulating levels of MOTS-c in patients with breast cancer treated with metformin.Aging · 2022PMID 36490309Accessed 2 Oct 2026
- 10Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors.Scientific reports · 2021PMID 34413391Accessed 2 Oct 2026
- 11PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) (262 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (humans[mh] OR human[tiab] OR participants[tiab] OR patients[tiab] OR volunteers[tiab]) (179 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (randomized controlled trial[pt] OR "clinical trial"[pt] OR "meta-analysis"[pt] OR "systematic review"[pt]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (mice[tiab] OR mouse[tiab] OR rat[tiab] OR rats[tiab]) AND (injection[tiab] OR treatment[tiab] OR administration[tiab] OR treated[tiab]) (72 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 16PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND ("MOTS-c"[tiab] OR MOTSc[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
- 18PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 19PubMed search: ("MOTS-c"[tiab] OR MOTSc[tiab] OR CB4211[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (20 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 20Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
- 21MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction.Journal of molecular medicine (Berlin, Germany) · 2019PMID 30725119Accessed 2 Oct 2026
- 22MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.Nature communications · 2021PMID 33473109Accessed 2 Oct 2026
- 23AOD-9604 Metabolic.Current opinion in investigational drugs (London, England : 2000) · 2004PMID 15134286Accessed 2 Oct 2026
- 24Mitochondrial-encoded MOTS-c prevents pancreatic islet destruction in autoimmune diabetes.Cell reports · 2021PMID 34320351Accessed 2 Oct 2026
Found an error? Report a correction.